摘要
目的评价全世界非小细胞肺癌治疗相关的医疗费用研究,以期为未来的非小细胞肺癌治疗的卫生经济学评估提供参考依据。方法计算机检索Cochrane图书馆、PubMed、MEDLINE和中文生物医学文献数据库等,纳入涉及非小细胞肺癌医疗费用的国内外文献进行统计分析。结果纳入10篇符合纳入标准的国外研究。从各国非小细胞肺癌治疗的医疗费用看,其人均费用差异较大,从人均37514美元、14722瑞士法郎、19212欧元到5070欧元不等。这与各国医疗费用的支付方式、治疗方案及国外研究一般基于初次诊断至几年后的费用有密切关系。非小细胞肺癌的医疗费用较高,且主要是住院治疗费用高,并随治疗时间的增加而增加。对国内非小细胞肺癌直接医疗费用的研究表明,其增长速度较快,且多数研究集中在单次住院费用,缺乏对患者跟踪研究的数据。结论非小细胞肺癌的直接医疗费用给患者带来巨大的经济负担,应从降低发病率和控制病种费用两方面入手。可从控烟和改善环境入手,同时应完善适合国情的肺癌治疗指南,推动规范化治疗。
Objective Review the status of the direct health cost of nonsmall-cell lung cancer, and to put forward policy recommendations. Methods Database including PubMed, Cochrane Library and Chinese BioMed were searched, and studies literatures about the direct health cost of nonsmall-cell lung cancer. Results Twenty two studies were analyzed in this paper including 20 foreign studies. Normally, international researches about direct medical cost of treating the nonsmall-cell lung cancer investigate total cost from the first diagnosis until several years later. The discrepancy in the results could be explained by different payments, treatment patterns and research methods in different countries. The direct medical cost of nonsmall-cell lung cancer is expensive especially the cost of in-patient. It＇s increase with the time of therapy. Most of the researches in China about direct medical cost of nonsmall-cell lung cancer focus on per in-patient fees. Conclusion Facing the increasingly heavy economic burden of nonsmall-cell lung cancer, to lower the incidence of this disease and to reduce the treatment related cost should be taken into account., the prevention of nonsmall-cell lung cancer carcinoma should be enhanced, Such as tobacco control, environment improvement, etc. A proper incentive mechanism should be established.
出处
《中国循证医学杂志》
CSCD
2008年第11期1012-1015,共4页
Chinese Journal of Evidence-based Medicine
